Neuland Laboratories Limited was established in 1984 and today is a publicly listed company headquartered in Hyderabad, India. Neuland is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry’s chemistry needs.
We provide solutions across the full range of the pharmaceutical industry’s chemistry requirements, from the synthesis of library compounds to supplying NCEs and advanced intermediates at various stages in the clinical life-cycle, as well as commercial launch. Our strength is our expertise in manufacturing of APIs and advanced intermediates from our US FDA approved facilities. Our core competency lies in the application of strong process chemistry to manufacturing in a regulatory compliant environment, which is supported by a strong, well-qualified team of more than 1000 employees.
For over three decades, Neuland has been at the forefront of facilitating and accelerating drug development and cGMP manufacturing of APIs. The Company’s technical and scientific teams provide comprehensive solutions and services to the global pharmaceutical industry.
Neuland has a presence in over 80 countries with more than 75% of our revenues accounted for by exports. The US and Europe are our key markets, accounting for 70% of total exports.
The Company has now filed 57 DMFs with the USFDA, over 400 DMFs in Europe, and many more with the various health authorities in Canada, Japan, Korea and Australia.
It has come to our notice that fraudulent recruitment offers are being extended on behalf of Neuland Laboratories Ltd. in the name of Board of Directors by certain individuals/entities.